Did You Know?

Editor’s Picks

Latest News

CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopeAMR is a leading cause of kidney transplant...

error: Content is protected !!